CTRI/2009/091/000658已完成3 期
Evaluation of efficacy and safety of propiverine versus oxybutynin in the treatment of patients with urinary incontinence: a randomized, open-label, comparative, active-controlled, multi-centre trial.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female patients aged between 18 - 65 years.
- •2.Patients with history of urgency or urge incontinence.
- •3.Patients with UI (≥7 episodes/week) and frequency (≥8 micturition/day).
- •4.Patients willing to give their informed consent.
排除标准
- •1.Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control.
- •2.Patients with postvoid residual volume > 100ml.
- •3.Patients on unstable dosage of any drug with anticholinergics or diuretic/ antidiuretic side effects.
- •4.Patients with allergy or previous life threatening side effects with anticholinergics/antispasmodic medication.
- •5.Patients with primary diagnosis of stress urinary incontinence.
- •6.Patients with conditions wherein anticholinergics are contraindicated.
- •7.Patients with hepatic/renal diseases.
- •8.Patients with diagnosed painful bladder syndrome.
- •9.Patients with uninvestigated voiding difficulty with risk of urinary retention, uninvestigated hematuria, or hematuria secondary to malignant disease.
- •10.Patents having acute UTIs or history of recurrent UTIs (>3 UTIs/year).
- •11.Indwelling catheter or bladder training within screening period.
- •12.Patients with bladder outlet obstruction.
- •13.Patients suffering from one of the following disorders;
- •Obstruction of the bowel, Significant degree of bladder outflow obstruction where urinary retention may be anticipated, Myasthenia gravis, Severe decreased gastrointestinal motility conditions, Severe ulcerative colitis, Toxic megacolon, Uncontrolled angle closure glaucoma, Moderate or severe hepatic impairment, Tachyarrhythmias, Autonomic neuropathy, Severe congestive heart failure, Prostatic hypertrophy, Hiatus hernia with reflux oesophagitis, Cardiac arrhythmia, Overt cerebral sclerosis.
研究者
相似试验
尚未招募
2 期
Evaluation of the effect onset with Propiverine hydrochloride(BUP-4) in Female Patients diagnosed as overactive bladder.overactive bladderJPRN-UMIN000012512Saitama Continence Conference30
进行中（未招募）
不适用
Efficacy of propiverine in patients with neurogenic detrusor overactivityneurogenic detrusor overactivityMedDRA version: 16.0Level: LLTClassification code 10012547Term: Detrusor hyperreflexiaSystem Organ Class: 100000004857EUCTR2012-003159-12-DEAPOGEPHA Arzneimittel GmbH
招募中
3 期
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126
招募中
3 期
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
已完成
不适用
A study on the usefulness of propiverine hydrochrorid (BUP-4)for dysuria caused to the oophorectomy followed by hysterectomydysuria caused to the bilateral oopholectomy followed by hysterectomyJPRN-UMIN000016088Keio Univercity School of Medicine,Department of Obstetrics and gynecology20